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ABSTRACT 
Objective: Osteoporosis is an extra-articular complication of rheumatoid arthritis (RA) with increased risk of fractures. FRAX is an online tool for 
assessing risk of osteoporotic fracture. However, the relationship between the FRAX score and disease specific risk factors has not yet been investigated 
in RA. Hence, we assessed 10-year fracture risk using FRAX and its relationship with disease activity score, inflammation and disease duration in RA. 
Methods: 50 RA patients enrolled and recruited consecutively in a special camp organized for RA patients on the occasion of World Osteoporosis 
Day, 2016to estimate the osteoporotic fracture risk from Rheumatology clinic. Predicted 10-year risk of hip fracture and major osteoporotic fracture 
(MOF) by FRAX score without information on bone mineral density (BMD). Inflammatory disease activity measures included disease activity score 
of 28 joints (DAS28), erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) were also measured. FRAX score also estimated in 40 age 
and sex matched healthy controls. 
Results: FRAX estimated significantly enhanced fracture risk in active RA, both for MOF (13.34±1.26%) and hip fracture (6.84±1.03%) as compared 
to controls for MOF (5.46±0.95%) and hip fracture (1.97±0.49%). In RA patients, MOF and hip fracture risk correlated with DAS28 and disease 
duration and MOF risk correlated with ESR and CRP. 
Conclusion: Active RA patients, even in the absence of BMD have an increased FRAX score indicating an enhanced 10-year probability of MOF and 
hip fracture. Long disease duration, high disease activity and an elevated ESR and CRP are potential disease specific risk factors for osteoporotic 
fractures in RA. 
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Rheumatoid arthritis (RA) is a chronic inflammatory and destructive 
joint disease characterized by chronic, progressive, systemic 
inflammation leading to substantial pain, disability, and other 
morbidities [1, 2]. Osteoporosis (OP) is an extra-articular 
complication of RA that results in increased risk of fractures and 
associated morbidity, mortality, and health care costs [3, 4]. The 
incidence of osteoporosis among patients with rheumatoid arthritis 
is 15-20% at the hip and spine [5]. 
In RA, bone metabolism is altered by the chronic inflammatory 
process via activation/inhibition of bone cell function [6], 
modification of body composition, corticosteroid use [7], diet [8] and 
low levels of physical activity. Moreover, during the active phase of 
the disease, elevated plasma concentrations of inflammatory 
cytokines, i.e. Interleukin-1 (IL-1), interleukin-6 (IL-6) and tumor 
necrosis factor-alpha (TNF-α) lead to reductions in fat-free mass 
with a loss of body cell mass and consequent reduction in muscle 
strength [9, 10]. This loss may negatively affect bone mineral density 
(BMD) because lean mass is a predictor of bone mass through its 
mechanical pull on the skeleton [11].  
The World Health Organization Fracture Risk Assessment Tool 
(FRAX) estimates a 10-year probability of sustaining a hip fracture 
and other major osteoporotic fractures (spine, forearm, hip, 
shoulder) [12] based on specific risk factors. The reasons for 
increased fracture risk in RA are complex. It may be due to chronic 
inflammation, inactivity and an increased risk of falling. Therefore, 
RA has been incorporated as a dichotomy (Yes or No) predictor in 
the FRAX algorithm and intuitively, one would expect that more 
severe or active disease would be associated with more severe 
osteoporosis [13]. However, risk factors of osteoporosis fracture in 
RA have not been well elucidated. Hence, we investigated disease 
specific risk factors that make an RA patient more prone to 
osteoporosis risk and also assessed 10-year fracture risk using 
country specific FRAX and its relationship with the disease duration, 
disease activity score and inflammation in RA patients. 
MATERIALS AND METHODS 
Patients 
Fifty RA patients fulfilling 2010 Rheumatoid Arthritis Classification 
Criteria were enrolled in this observational study from a 
Rheumatology outpatient clinic. It was a special camp organized for RA 
patients on the occasion of World Osteoporosis Day, 2016 [14] to 
estimate the osteoporotic fracture risk and the event was publicized 
previously. All consecutive RA patients who reported for the camp 
were recruited in this survey. FRAX score was also estimated in 40 age 
and sex matched healthy controls. Healthy controls were recruited 
from among the hospital clinic staff and the patient attendants. 
All the patients included had active RA defined by the presence of 
disease activity score of 28 joints (DAS28>3.2). Eligible patients 
were biologic naïve and on stable doses of synthetic disease 
modifying anti-rheumatic drugs (DMARDs) [methotrexate (15 
mg/week), hydroxychloroquine (400 mg/day), sulfasalazine (2-3 
g/day) or leflunomide (20 mg/day)]+oral glucocorticoids (≤10 
mg/day prednisone or equivalent) before entering the study.  
Assessment of inflammatory disease activity  
• DAS28 was used to assess disease activity of 28 joints by a 
composite measure, which is a linear sum of four parameters 
including tender joint count (TJC), swollen joint count (SJC), patient 
global assessment of general health on a visual analogue scale (VAS), 
and erythrocyte sedimentation rate (ESR) [15].  
• ESR was measured by Westergren method.  
• C-reactive protein (CRP) level was determined using a standard 
commercial kit. 
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Assessment of FRAX score 
Predicted 10 y risks of hip fracture and major osteoporotic fracture 
(MOF) were calculated online by India specific FRAX without 
information on BMD for every patient. FRAX predictors determined 
included: age at index date, sex, BMI (most recent), previous fracture 
at any site (ever before, yes/no), parent fractured hip, current 
smoking status (most recent; yes/no), alcohol use (the daily number 
of units was ≥3, yes/no), oral glucocorticoid use (yes/no), RA (ever 
before, yes/no) and secondary osteoporosis. 
Ethics approval 
This survey was done as a part of the World Osteoporosis Day 
activity at our Rheumatology clinic. Ethics approval was not 
required for this study as it was not affecting the patient’s integrity. 
Statistical analysis 
Results were expressed as mean±standard error of mean (SEM). 
Descriptive analysis was done according to different parameters and 
Pearson correlation analysis was used to evaluate the correlation 
between FRAX score (10-year MOF and hip fracture risk) and 
disease activity, disease duration and inflammatory disease 
variables. A two-sided p<0.05 was considered statistically 
significant. Statistical analysis was done using the sigma stat 3.5 
version for Windows 7.0.  
RESULTS 
The demographic and clinical characteristics of RA patients and healthy 
controls are presented in table 1. The mean age (±SEM) of the patients 
was 67.62±1.05 y with a mean disease duration of 10.19±1.38 y. 
 
Table 1: Demographic and disease characteristics of rheumatoid arthritis patients and healthy controls 
Variables Rheumatoid arthritis  Controls p-value 
Age,years 67.62±1.05 66.03±1.95 NS 
Sex (F: M) 46:4 34:6  
Disease Duration,yrs 10.19±1.38 -- -- 
BMI, kg/m2  26.73±0.90 25.78±0.72 0.23 
MOF (%) 13.34±1.26 5.46±0.95 0.01* 
HF (%) 6.84±1.03 1.97±0.49 0.001* 
DAS28-ESR 5.42±0.20 ----  
ESR, mm 1sthour 44.08±2.94 16.85±0.70 0.01* 
CRP, mg/dl 16.39±3.00 3.84±0.16 0.01* 
Values are expressed as mean±SEM, n=50-number of rheumatid arthritis patients, n=40 number of healthy controls, F-Female, M-Male, BMI-body 
mass index, MOF-major osteoporotic fracture, HF-hip fracture, ESR-erythrocyte sedimentation rate, CRP-C-reactive protein, DAS28-disease activity 
score of 28 joint counts. *p<0.05, statistically significant 
 
Assessment of disease activity scores  
All of the study patients had an active disease with moderate to high 
disease activity, as reflected by DAS 28 score ≥3. 2. The mean DAS28 
score in the participating RA patients was 5.42±0.20.  
Assessment of the inflammatory profile 
In order to establish the inflammatory status, we assessed the values 
of ESR and CRP. The levels of inflammatory measures, ESR (p<0.01) 
and CRP (p<0.03) were significantly higher in RA patients as 
compared with healthy controls (table 1).  
Assessment of FRAX score  
In order to assess the fracture risk, we used the FRAX algorithm that 
showed the 10-year risk for a MOF and hip fracture was significantly 
(p<0.05) higher in RA patients as compared to healthy controls 
(table 1). 
Association of FRAX scores with disease activity and disease 
duration 
Pearson correlation analysis was performed to investigate the 
relationship between MOF, hip fracture with DAS28, inflammatory 
measures and disease duration. In RA patients, 10-year MOF and hip 
fracture risk positively correlated with DAS 28 (r=0.64, p=0.002), 
(r=0.52, p=0.01), disease duration (r= 0.58, p=0.001) (r= 0.51, 
p=0.01) and CRP (r= 0.54, p=0.01) (r= 0.55, p=0.001) respectively 
(table 2). There was a significant correlation between 10-year MOF 
and ESR (r= 0.39, p=0.04) indicating that high fracture risk was 
associated with inflammation. 
  
Table 2: Correlation of FRAX score with disease variables in rheumatoid arthritis patients 
Variables MOF  Hip fracture 
Disease duration,yrs 0.58 0.01* 0.51 0.04* 
BMI, kg/m2 0.32 0.12 0.22 0.19 
DAS28-ESR 0.64 0.01* 0.52 0.01* 
ESR, mm 1st h  0.39 0.04* 0.31 0.15 
CRP, mg/dl 0.54 0.001* 0.55 0.01* 




The present study is novel for several reasons. This study 
demonstrates that in patients with active RA, even in the absence of 
information on BMD, FRAX algorithm predicts a high 10-year risk 
probability of MOF and hip fracture as compared to controls. It has 
also suggested that longer disease duration, high disease activity and 
an elevated ESR and CRP are potential risk factors for 10 y 
probability of fracture in RA. To the best of our knowledge, this is 
the first study to report a plausible association between FRAX score 
(10 y MOF and hip fracture probability) and disease-specific risk 
factors (disease duration, DAS 28, ESR and CRP) responsible for 
fracture in patients with RA without information on BMD. Although 
FRAX score and disease activity measures, as well as some other 
factors, have previously been assessed by other investigators in RA 
patients [16,17], our results regarding the relationship of FRAX 
score with disease duration, high disease activity, ESR and CRP 
levels without BMD are novel and possibly contribute to the proof of 
the causative mechanisms of osteoporosis in RA.  
The prevalence of osteoporosis in RA patients is approximately 
twice that in the general population [18]. RA is the only secondary 
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cause of osteoporosis that is considered independent of bone 
density in the FRAX algorithm [19]. The underlying reasons for the 
increased fracture risk in RA are complex. These may include 
chronic inflammation, increased disease activity, impaired physical 
activity and an increased risk of falling [20, 21]. The various risk 
factors for osteoporosis are history of fracture, gender, age, family 
history of osteoporosis, estrogen deficiency, low calcium intake, 
vitamin D deficiency, use of corticosteroids, smoking and alcohol 
consumption [22] but the present study focused on the disease-
specific risk factors associated with RA like age, sex, disability, 
previous non-vertebral fracture, disease duration, active disease and 
use of glucocorticoids. Although many studies document a correlation 
between various parameters of disease activity or severity and 
decreased bone density, the relationship between the FRAX score and 
disease-specific measures have not yet been explored for both MOF 
and hip fracture in RA. Hence, using the FRAX algorithm, we assessed 
fracture risk and its relationship with the disease duration, disease 
activity score and inflammatory measures in RA patients.  
In the present study, country-specific FRAX score has indicated an 
increased 10 y risk of MOF and hip fracture in patients with RA as 
compared to healthy controls. Other studies have also shown a 
similar increase in FRAX score in RA patients [23]. The mean of MOF 
risk (13.34%) and hip fracture risk (6.84%) observed in the present 
study is comparable to that reported by Klop et al. [23].  
RA may appear to be a risk factor for fractures only through 
association with other risk factors which are more directly 
responsible for the observed effects [17]. Conventional risk factors 
for osteoporosis in RA include the use of glucocorticoids, longer 
disease duration, high disability scores, low body weight and age 
[24]. Our data seem to favour this possibility, and the factors which 
appeared to have the most predictive value were disease duration, 
inflammatory state and severity of the disease process. Present study 
results observed a relationship between FRAX score (10 y MOF and 
hip fracture probability) and disease duration. Disease duration was 
the strongest predictor of future fractures in this study with a disease 
duration of>10 y. Our study results are in accordance with the 
previous study that demonstrated a significant association of incident 
fractures with duration of disease [16]. This might be due to the fact 
that RA patients have been exposed for greater lengths of time to risk 
factors for bone loss such as corticosteroid use, lower estrogen levels, 
prolonged immobilization and greater inflammatory state.  
The DAS28 is a widely used score for evaluation of disease activity in 
RA [15]. Previous studies have associated various disease 
parameters seen in RA patients with disease duration [16] and 
DAS28 [25, 26]. A recent study by Ileana et al. showed that DAS28 
were statistically associated with osteoporosis in RA patients [27]. 
In the present study, DAS28 correlates with a 10 y MOF and hip 
fracture risk in RA patients. Our study is the first to convincingly 
show the association of DAS28 with MOF and hip fractures in RA 
patients. This indicating an active disease and its severity are 
potential risk factors for osteoporotic fracture in RA.  
Chronic inflammation has been recognized as a potential risk factor for 
osteoporosis and fracture [28]. In the present study, higher levels of 
ESR and CRP in RA as compared with controls depict enhanced 
inflammatory state responsible for increased fracture risk in RA. Our 
study results suggest a significant association of the inflammatory 
process itself represented by an elevated ESR and CRP in RA patients.  
In a recent study of American women (mean age 46 y, 194 fractures) 
published by Ishii and colleagues, fracture hazard increased 
significantly for values of hs-CRP above 3 mg/l [29]. The Health 
Aging and Body Composition Study also showed that the incidence 
of fracture was also highest in subjects with the highest CRP and IL-6 
but the trend was not statistically significant [30]. However, in the 
present study, a significant association of CRP with both MOF and 
hip fracture and association of ESR with MOF in RA patients showed 
that how low-grade inflammation leads to an increased risk for 
fractures in RA. This suggests in patients with RA, the degree of the 
inflammatory process as assessed by ESR and CRP, predicts a bone 
loss and might be of value in identifying patients at risk of 
developing osteoporosis and offers clues as to the mechanism of 
such an effect. 
LIMITATIONS 
The present study has some limitations, the number of patients was 
relatively small, and the current study was a single-centre study. 
There are limitations to the FRAX guidelines. FRAX does not 
incorporate every clinical variable that may be important in fracture 
risk assessment (e. g., fall risk) and lacks information on dose-
response relationships (e. g., glucocorticoid, DMARD, biologic dose). 
Nonetheless, FRAX represents an important starting point in the 
complex task of risk assessment and fracture prevention, but should 
not be regarded as a substitute for clinical judgment. Several 
important operational issues need to be considered in using FRAX as 
part of day-to-day patient care. Other factors such as exposure to 
DMARDs and treatment status also need to be considered before any 
therapeutic decision is taken to manage the osteoporotic risk.  
Despite its limitations, this study has notable strengths. It provides 
an important insight into the association of FRAX score and disease-
specific factors that can influence therapeutic strategies. 
CONCLUSION 
We conclude that the 10 y fracture probability in RA estimated with 
the FRAX algorithm is increased and is associated with long disease 
duration, disease severity and inflammatory disease burden–
disease-specific risk factors. The various factors observed during the 
camp like longer disease duration increased disease severity and 
increased inflammatory markers affected the overall score as they 
increased the risk. Hence, use of FRAX without BMD may be 
appropriate when BMD is not readily available or to identify 
individuals who may benefit from a BMD measurement. 
ABBREVIATIONS 
RA-rheumatoid arthritis, BMD-bone mineral density, MOF-major 
osteoporotic fracture, DAS28-disease activity score of 28 joints, ESR-
erythrocyte sedimentation rate, CRP-C-reactive protein, OP-
osteoporosis, IL-1-interleukin 1, IL-6-interleukin-6, TNF-α-tumor 
necrosis factor-alpha, DMARDs-disease modifying anti-rheumatic 
Drugs, TJC-tender joint count, SJC-swollen joint count, VAS-patient 
global assessment of general health on a visual analogue scale, BMI-
body mass index, SEM-standard error of mean. 
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